プロテアソーム阻害剤ベラクトシンAシス型異性体の構造活性相関研究

Structure-Activity Relationship Study of Unnatural *cis*-Isomer of Belactosin A, a Potent Proteasome Inhibitor

Shuhei Kawamura¹, Yuka Unno², Anja List³, Kaori Itagaki¹, Akira Mizuno¹, Motohiro Tanaka⁴, Takuma Sasaki⁴, Michael Groll³, Akira Asai², Mitsuhiro Arisawa¹, and Satoshi Shuto¹.

Hokkaido University, Sapporo, 060-0812, Japan. 2. University of Shizuoka, Shizuoka, 422-8526, Japan.
Center for Integrated Protein Science at the Department Chemie, Lehrstuhl für Biochemie, Technische Universität München, Garching D-85747, Germany. 4. Aichi Gakuin University, Nagoya, 464-8650, Japan

Proteasome is a multicatalytic proteinase complex which works on the turnover of large portion of intracellular proteins. In 2003, for the first time as a proteasome inhibitor, bortezomib was approved by FDA for the treatment of patients with relapsed or refractory multiple myeloma, and many proteasome inhibitors have been studied as potent anti-cancer drug candidates so far.

Belactosin A is a natural product isolated from *Streptomyces Sp.* [1] which has anti-proliferative activity in human cancer cell lines due to the proteasome inhibition [2]. Previously, we synthesized stereo- and regioisomers of Belactosin A and found that *cis*-isomer **1** of belactosin A has somewhat greater proteasome inhibitory activity than belactosin A itself [3] and their synthetic precursors **2**, having hydrophobic substituents, are much more potent [4]. (Fig. 1)



Figure 1. Structure of belactosin A and its derivatives.

We have newly designed and synthesized a series of *cis*-belactosin A derivatives and found a highly potent proteasome inhibitor **3**, which inhibits the chymotrypsin-like activity of proteasome as strong as bortezomib ($IC_{50} = 4.5 \text{ nM}$). We will present the details of these results.

<参考文献>

[1] Asai, A et al. J. Antibiot. 2000, 53, 81. [2] Asai, A. et al. Biochem. Pharmacol. 2004, 67, 227. [3] Shuto, S. et al.
Org. Lett. 2008, 10, 3571. [4] Shuto, S. et al. Org. Biomol. Chem. 2009, 7, 1868.

発表者給	约下	
氏名	川村 周平	
所属	北海道大学生命科学院生命医薬科学コース	
学年	D2	
研究室	創薬有機化学研究室	The second states